SCHEMBL24843852

SCHEMBL24843852

COc1cc2nc3ccccc3c(NC3CCNCC3)c2cc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EHMT2 Q96KQ7 14/20 0.69
▸ NSD2 O96028 1/20 0.55
▸ CYP1A2 P05177 3/20 0.53
▸ HSD17B10 Q99714 3/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ CLK4 Q9HAZ1 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ TP53 P04637 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ HIF1A Q16665 1/20 0.53
▸ CHEK1 O14757 1/20 0.50
▸ CHEK2 O96017 1/20 0.50
▸ KDM1A O60341 1/20 0.48
▸ RCOR1 Q9UKL0 1/20 0.48
▸ IRAK4 Q9NWZ3 1/20 0.47
▸ USP2 O75604 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30063343 0.93 EHMT2 (0.61) EHMT2NSD2CYP1A2HSD17B10ALDH1A1
SCHEMBL24844128 0.93 EHMT2 (0.61) EHMT2NSD2CYP1A2HSD17B10ALDH1A1
SCHEMBL30063365 0.91 EHMT2 (0.59) EHMT2NSD2CYP1A2HSD17B10ALDH1A1
SCHEMBL24843911 0.91 EHMT2 (0.59) EHMT2NSD2CYP1A2HSD17B10ALDH1A1
SCHEMBL20745542 0.89 EHMT2 (0.57) EHMT2NSD2CYP1A2HSD17B10ALDH1A1
SCHEMBL24844168 0.88 EHMT2 (0.56) EHMT2NSD2CYP1A2HSD17B10ALDH1A1
SCHEMBL30063364 0.88 EHMT2 (0.56) EHMT2NSD2CYP1A2HSD17B10ALDH1A1
SCHEMBL25489870 0.88 EHMT2 (0.72) EHMT2NSD2LMNA
SCHEMBL24844080 0.86 EHMT2 (0.66) EHMT2CHEK1CHEK2
SCHEMBL30063292 0.86 EHMT2 (0.66) EHMT2CHEK1CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3668863-B1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2025-03-19 — — EP disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 — — US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 EHMT2 2/4885NSD2 133/4885CYP1A2 4410/4885
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 EHMT2 2/4885NSD2 133/4885CYP1A2 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback